Professor Ivan Torenkov, Corresponding Member of the Russian Academy of Sciences, announced that clinical trials of a drug developed by Volgograd University scientists for the treatment of diabetes and obesity will begin in 2022.
The professor points out that clinical tests of the innovative drug called “Dipyarone” for the treatment of diabetes and obesity, which is unparalleled in the world, will begin this year, according to the Russian “TASS” agency.
Normalizes the level of glucose in the blood
He adds: Taking this drug helps to normalize the level of glucose in the blood, which is a way to raise the effectiveness of treating diabetes, metabolic syndrome and obesity. It can be used as a standalone treatment for early-stage diabetes.
The professor says: “This drug is unique and original in its class, and has no equal in the world. This drug stimulates the production of incretins (intestinal hormones), which, after eating, stimulates the production of these hormones, which in turn stimulates the secretion of insulin, which accelerates the transmission of “When this mechanism is disrupted, as in type 2 diabetes, where the production of incretins does not provide the secretion of the necessary amount of insulin, sugar remains in the blood.”